ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzumab Govitecan by Trop-2 Expression and UGT1A1 Status in the TROPHY-U-01 Study for LA or mUC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzumab Govitecan by Trop-2 Expression and UGT1A1 Status in the TROPHY-U-01 Study for LA or mUC"

By Insights from 2023 ASCO® Annual Meeting FEATURING Scott Tagawa

154 views

June 8, 2023

0 Comments

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini

15:58

Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers

22:19

Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde

14:00

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde

17:32

Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

06:01

ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles

19:30

Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas

30:03

UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander

11:29

Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles

13:54

AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde

09:12

AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde

05:59

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Ved…

Feat. T. Powles

15:50

Petros Grivas

Year in Review: Bladder Cancer

28:53

OncoAlert

Year in Review: Best of Bladder Cancer Updates in 2023

Feat. A. Apolo

17:03

Total Health

Emerging Trends in Localized Bladder Cancer in 2024

Feat. N. Gopal

29:25

Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

12:54

Scripps MD Anderson Cancer Center

Recent Advances in Therapy for Bladder Cancer

Feat. M. Bhangoo

05:48

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "UNITE Study - Outcomes in Patients Wit…

Feat. A. Nizam

09:22

ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201…

Feat. P. Grivas, C. Park

10:29

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "AMBASSADOR Alliance A031501 Study of P…

Feat. A. Apolo

Login

Login

Join VuMedi

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzumab Govitecan by Trop-2 Expression and UGT1A1 Status in the TROPHY-U-01 Study for LA or mUC"

Related Content